{
  "patient_id": "gerald_t",
  "extraction_metadata": {
    "extracted_from": ["01_Prior_Auth_Request_Form.pdf", "02_Laboratory_Results.pdf", "03_MRI_Spine_Report.pdf"],
    "extraction_date": "2026-02-06",
    "extraction_method": "clinical_document_extraction"
  },

  "demographics": {
    "first_name": "Gerald",
    "last_name": "Thompson",
    "date_of_birth": "1972-01-30",
    "age": 54,
    "gender": "Male",
    "ethnicity": "Caucasian",
    "address": { "street": "1847 North Clark Street", "city": "Chicago", "state": "IL", "zip": "60614" },
    "phone": "312-555-0198",
    "mrn": "GERALD_T",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "insurance": {
    "primary": {
      "payer_name": "UHC",
      "payer_id": "UHC",
      "plan_name": "UnitedHealthcare Navigate Plus",
      "plan_type": "HMO",
      "member_id": "UHC678912345",
      "group_number": "IL-HMO-2024",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  },

  "prescriber": {
    "name": "Dr. Robert Kowalski",
    "credentials": "MD, FACR",
    "npi": "1678912345",
    "specialty": "Rheumatology",
    "practice_name": "Northwestern Rheumatology Associates",
    "address": { "street": "675 N St Clair Street, Suite 1400", "city": "Chicago", "state": "IL", "zip": "60611" },
    "phone": "312-555-0500",
    "fax": "312-555-0501",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "medication_request": {
    "medication_name": "Infliximab",
    "brand_name": "Inflectra",
    "generic_name": "infliximab-dyyb",
    "j_code": "Q5103",
    "product_type": "preferred_biosimilar",
    "dose": "5mg/kg",
    "route": "Intravenous infusion",
    "frequency": { "induction": "Weeks 0, 2, 6", "maintenance": "Every 6 weeks" },
    "duration_requested": "12 months initial authorization",
    "quantity_requested": "4 infusions",
    "site_of_care": "Outpatient infusion center",
    "start_date_requested": "2026-02-22",
    "diagnosis": "Ankylosing spondylitis",
    "icd10_code": "M45.0",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "diagnoses": [
    {
      "rank": "primary",
      "icd10_code": "M45.0",
      "description": "Ankylosing spondylitis of multiple sites in spine",
      "status": "active",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "rank": "secondary",
      "icd10_code": "M46.1",
      "description": "Sacroiliitis, not elsewhere classified",
      "status": "active",
      "source_document": "03_MRI_Spine_Report.pdf"
    }
  ],

  "disease_activity": {
    "assessment_date": "2026-01-10",
    "basdai_score": 7.2,
    "basdai_interpretation": "High disease activity (BASDAI >=4)",
    "basfi_score": 6.8,
    "basfi_interpretation": "Significant functional impairment",
    "asdas_crp": 3.8,
    "asdas_interpretation": "Very high disease activity (ASDAS >3.5)",
    "disease_severity": "severe",
    "hla_b27": "Positive",
    "source_documents": ["01_Prior_Auth_Request_Form.pdf", "03_MRI_Spine_Report.pdf"]
  },

  "clinical_history": {
    "chief_complaint": "Severe inflammatory back pain, progressive spinal stiffness, and bilateral sacroiliitis unresponsive to NSAIDs",
    "history_of_present_illness": "54-year-old male with HLA-B27 positive ankylosing spondylitis diagnosed 2018. BASDAI 7.2, ASDAS-CRP 3.8 indicating very high disease activity. MRI shows active bilateral sacroiliitis with bone marrow edema and syndesmophyte formation at T12-L1 and L4-L5. Failed 3 different NSAIDs at maximum dose (naproxen, indomethacin, celecoxib), each for minimum 4 weeks. Sulfasalazine tried for peripheral arthritis but ineffective for axial disease. Morning stiffness >2 hours, unable to perform occupational duties (construction supervisor) due to limited spinal mobility.",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "prior_treatments": [
    {
      "medication_name": "Naproxen",
      "drug_class": "NSAID",
      "dose": "500mg BID",
      "start_date": "2023-01-01",
      "end_date": "2023-03-01",
      "duration_weeks": 8,
      "outcome": "inadequate_response",
      "outcome_description": "Minimal improvement in BASDAI score despite maximum dose",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "medication_name": "Indomethacin",
      "drug_class": "NSAID",
      "dose": "75mg SR BID",
      "start_date": "2023-04-01",
      "end_date": "2023-06-15",
      "duration_weeks": 10,
      "outcome": "inadequate_response",
      "outcome_description": "Partial improvement but persistent high disease activity with BASDAI >6",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "medication_name": "Celecoxib",
      "drug_class": "NSAID (COX-2 selective)",
      "dose": "200mg BID",
      "start_date": "2023-08-01",
      "end_date": "2025-11-01",
      "duration_weeks": 117,
      "outcome": "inadequate_response",
      "outcome_description": "Continued use for partial symptom relief but disease activity remained high (BASDAI >7, ASDAS >3.5)",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "medication_name": "Sulfasalazine",
      "drug_class": "csDMARD",
      "dose": "2g daily",
      "start_date": "2024-06-01",
      "end_date": "2025-03-01",
      "duration_weeks": 39,
      "outcome": "inadequate_response",
      "outcome_description": "No improvement in axial symptoms. Per ACR/SAA guidelines, csDMARDs are not effective for axial SpA.",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  ],

  "laboratory_results": {
    "collection_date": "2026-01-08",
    "ordering_provider": "Dr. Robert Kowalski",
    "facility": "Northwestern Memorial Lab",
    "report_status": "FINAL",
    "source_document": "02_Laboratory_Results.pdf",
    "panels": {
      "cbc": {
        "panel_name": "Complete Blood Count (CBC)",
        "results": [
          {"test": "WBC", "value": 8.8, "unit": "x10^9/L", "reference_range": "4.5-11.0", "flag": null},
          {"test": "Hemoglobin", "value": 13.5, "unit": "g/dL", "reference_range": "13.5-17.5", "flag": null},
          {"test": "Platelets", "value": 310, "unit": "x10^9/L", "reference_range": "150-400", "flag": null}
        ]
      },
      "inflammatory_markers": {
        "panel_name": "Inflammatory Markers",
        "results": [
          {"test": "CRP", "value": 22, "unit": "mg/L", "reference_range": "0-5", "flag": "H"},
          {"test": "ESR", "value": 35, "unit": "mm/hr", "reference_range": "0-15", "flag": "H"}
        ]
      },
      "hla_typing": {
        "panel_name": "HLA Typing",
        "results": [
          {"test": "HLA-B27", "value": "Positive", "reference_range": "Negative", "flag": "Positive"}
        ]
      },
      "hepatic_panel": {
        "panel_name": "Hepatic Panel",
        "results": [
          {"test": "ALT", "value": 18, "unit": "U/L", "reference_range": "7-56", "flag": null},
          {"test": "Creatinine", "value": 1.0, "unit": "mg/dL", "reference_range": "0.7-1.3", "flag": null}
        ]
      }
    },
    "interpretation": "Elevated CRP (22) and ESR (35) consistent with active axial inflammation. HLA-B27 positive. CBC and metabolic panel normal."
  },

  "pre_biologic_screening": {
    "status": "COMPLETE",
    "tuberculosis_screening": { "status": "COMPLETE", "test_performed": "QuantiFERON-TB Gold Plus", "result": "Negative", "cleared_for_biologic": true },
    "hepatitis_b_screening": { "status": "COMPLETE", "interpretation": "HBV negative with immunity from vaccination", "cleared_for_biologic": true },
    "hepatitis_c_screening": { "status": "COMPLETE", "result": "Non-reactive", "cleared_for_biologic": true }
  },

  "pa_criteria_assessment": {
    "diagnosis_confirmed": { "met": true, "evidence": "HLA-B27 positive AS with MRI-confirmed active sacroiliitis and syndesmophytes" },
    "disease_severity_documented": { "met": true, "evidence": "BASDAI 7.2, ASDAS-CRP 3.8, CRP 22 â€” very high disease activity" },
    "conventional_therapy_failed": {
      "met": true,
      "therapies_tried": [
        {"medication": "Naproxen", "outcome": "inadequate_response", "duration_adequate": true},
        {"medication": "Indomethacin", "outcome": "inadequate_response", "duration_adequate": true},
        {"medication": "Celecoxib", "outcome": "inadequate_response", "duration_adequate": true}
      ]
    },
    "step_therapy_satisfied": { "met": true, "evidence": "Failed >=2 NSAIDs at maximum dose for >=4 weeks each per ASAS/EULAR guidelines" },
    "pre_biologic_screening_complete": { "met": true },
    "fda_approved_indication": { "met": true, "indication": "Active ankylosing spondylitis" }
  },

  "overall_pa_readiness": {
    "status": "READY_FOR_SUBMISSION",
    "all_clinical_criteria_met": true,
    "recommendation": "All criteria met. HLA-B27 positive AS with very high disease activity (ASDAS 3.8) and failure of 3 NSAIDs. Submit immediately."
  }
}
